EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Treatment of relapsed/refractory MCL

Elisabeth Silkenstedt iD, Martin Dreyling iD

Blood · 13.02.2025 · 145 (7) · 673-682

DOI: 10.1182/blood.2023022353 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Blood, erschienen am 13.02.2025. Verfasst von Elisabeth Silkenstedt und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III, Ludwig Maximilian University Hospital, Munich, Germany. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 89 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphoma that is clinically characterized by its heterogeneous behavior, with courses ranging from indolent to highly aggressive cases with limited prognosis. Targeted treatment alternatives in first-line and relapse settings are more and more shaping the therapeutic landscape of MCL. The development and implementation of new targeted and immunotherapeutic approaches have already improved outcomes for patients with MCL with refractory or relapsed disease. However, long-term prognosis is still limited, and patients with relapsed/refractory (R/R) disease, especially those failing Bruton tyrosine kinase (BTK) inhibitor treatment, usually have a dismal outcome. This review summarizes the current and emerging treatment options for R/R MCL, focusing on the implementation of combined targeted treatment strategies such as BTK inhibitors and BCL2 inhibitors, as well as immune-therapeutic approaches including chimeric antigen receptor T cells and bispecific antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellNeoplasm Recurrence, LocalHumansAgammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsAntibodies, BispecificDrug Resistance, NeoplasmRecurrenceImmunotherapy, AdoptiveImmunotherapyProto-Oncogene Proteins c-bcl-2

Substanzen

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsAntibodies, BispecificBTK protein, humanProto-Oncogene Proteins c-bcl-2

Autor:innen und Institutionen

  • Department of Medicine III, Ludwig Maximilian University Hospital, Munich, Germany.

ORCID-Profile: Elisabeth Silkenstedt, Martin Dreyling

Zitieren

APA

Silkenstedt, E., & Dreyling, M. (2025). Treatment of relapsed/refractory MCL. Blood, 145(7), 673-682. https://doi.org/10.1182/blood.2023022353

Vancouver

Silkenstedt E, Dreyling M. Treatment of relapsed/refractory MCL. Blood. 2025;145(7):673-682. doi:10.1182/blood.2023022353

BibTeX
@article{Silkenstedt2025,
  author = {Silkenstedt, Elisabeth and Dreyling, Martin},
  title = {Treatment of relapsed/refractory MCL},
  journal = {Blood},
  year = {2025},
  volume = {145},
  number = {7},
  pages = {673--682},
  doi = {10.1182/blood.2023022353}
}
Kostenlos starten →